Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 57

1.

Pathophysiological and cognitive mechanisms of fatigue in multiple sclerosis.

Manjaly ZM, Harrison NA, Critchley HD, Do CT, Stefanics G, Wenderoth N, Lutterotti A, Müller A, Stephan KE.

J Neurol Neurosurg Psychiatry. 2019 Jun;90(6):642-651. doi: 10.1136/jnnp-2018-320050. Epub 2019 Jan 25. Review.

2.

GDP-l-fucose synthase is a CD4+ T cell-specific autoantigen in DRB3*02:02 patients with multiple sclerosis.

Planas R, Santos R, Tomas-Ojer P, Cruciani C, Lutterotti A, Faigle W, Schaeren-Wiemers N, Espejo C, Eixarch H, Pinilla C, Martin R, Sospedra M.

Sci Transl Med. 2018 Oct 10;10(462). pii: eaat4301. doi: 10.1126/scitranslmed.aat4301.

3.

Memory B Cells Activate Brain-Homing, Autoreactive CD4+ T Cells in Multiple Sclerosis.

Jelcic I, Al Nimer F, Wang J, Lentsch V, Planas R, Jelcic I, Madjovski A, Ruhrmann S, Faigle W, Frauenknecht K, Pinilla C, Santos R, Hammer C, Ortiz Y, Opitz L, Grönlund H, Rogler G, Boyman O, Reynolds R, Lutterotti A, Khademi M, Olsson T, Piehl F, Sospedra M, Martin R.

Cell. 2018 Sep 20;175(1):85-100.e23. doi: 10.1016/j.cell.2018.08.011. Epub 2018 Aug 30.

4.

Unfavorable Structural and Functional Outcomes in Myelin Oligodendrocyte Glycoprotein Antibody-Associated Optic Neuritis.

Jelcic I, Hanson JVM, Lukas S, Weber KP, Landau K, Pless M, Reindl M, Weller M, Martin R, Lutterotti A, Schippling S.

J Neuroophthalmol. 2019 Mar;39(1):3-7. doi: 10.1097/WNO.0000000000000669.

PMID:
30015656
5.

Transient impairment of olfactory threshold in acute multiple sclerosis relapse.

Bsteh G, Hegen H, Ladstätter F, Berek K, Amprosi M, Wurth S, Auer M, Di Pauli F, Deisenhammer F, Lutterotti A, Berger T.

Mult Scler Relat Disord. 2018 Jul;23:74-77. doi: 10.1016/j.msard.2018.05.006. Epub 2018 May 26.

PMID:
29783156
6.

Challenges and needs in experimental therapies for multiple sclerosis.

Lutterotti A.

Curr Opin Neurol. 2018 Jun;31(3):263-267. doi: 10.1097/WCO.0000000000000560. Review.

PMID:
29608446
7.

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.

Kappos L, Bar-Or A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F; EXPAND Clinical Investigators.

Lancet. 2018 Mar 31;391(10127):1263-1273. doi: 10.1016/S0140-6736(18)30475-6. Epub 2018 Mar 23. Erratum in: Lancet. 2018 Nov 17;392(10160):2170.

PMID:
29576505
8.

Change of olfactory function as a marker of inflammatory activity and disability progression in MS.

Bsteh G, Hegen H, Ladstätter F, Berek K, Amprosi M, Wurth S, Auer M, Di Pauli F, Deisenhammer F, Reindl M, Berger T, Lutterotti A.

Mult Scler. 2019 Feb;25(2):267-274. doi: 10.1177/1352458517745724. Epub 2017 Nov 29.

PMID:
29185867
9.

Human antibodies against the myelin oligodendrocyte glycoprotein can cause complement-dependent demyelination.

Peschl P, Schanda K, Zeka B, Given K, Böhm D, Ruprecht K, Saiz A, Lutterotti A, Rostásy K, Höftberger R, Berger T, Macklin W, Lassmann H, Bradl M, Bennett JL, Reindl M.

J Neuroinflammation. 2017 Oct 25;14(1):208. doi: 10.1186/s12974-017-0984-5.

10.

CD4+ T-Cell Reactivity to Orexin/Hypocretin in Patients With Narcolepsy Type 1.

Ramberger M, Högl B, Stefani A, Mitterling T, Reindl M, Lutterotti A.

Sleep. 2017 Mar 1;40(3). doi: 10.1093/sleep/zsw070.

11.

Is it Time for Immunotherapy Trials in Narcolepsy?

Lutterotti A.

J Clin Sleep Med. 2017 Mar 15;13(3):363-364. doi: 10.5664/jcsm.6478. No abstract available.

12.

Restoring immune tolerance in neuromyelitis optica: Part II.

Bar-Or A, Steinman L, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Smith TJ, Yeaman MR.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e277. doi: 10.1212/NXI.0000000000000277. eCollection 2016 Oct. Review.

13.

Restoring immune tolerance in neuromyelitis optica: Part I.

Steinman L, Bar-Or A, Behne JM, Benitez-Ribas D, Chin PS, Clare-Salzler M, Healey D, Kim JI, Kranz DM, Lutterotti A, Martin R, Schippling S, Villoslada P, Wei CH, Weiner HL, Zamvil SS, Yeaman MR, Smith TJ.

Neurol Neuroimmunol Neuroinflamm. 2016 Sep 7;3(5):e276. doi: 10.1212/NXI.0000000000000276. eCollection 2016 Oct. Review.

14.

Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection.

Misselwitz B, Epprecht J, Mertens J, Biedermann L, Scharl M, Haralambieva E, Lutterotti A, Weber KP, Müllhaupt B, Chaloupka K.

Case Rep Gastroenterol. 2016 May 19;10(1):108-14. doi: 10.1159/000444011. eCollection 2016 Jan-Apr.

15.

Long Term Clinical Prognostic Factors in Relapsing-Remitting Multiple Sclerosis: Insights from a 10-Year Observational Study.

Bsteh G, Ehling R, Lutterotti A, Hegen H, Di Pauli F, Auer M, Deisenhammer F, Reindl M, Berger T.

PLoS One. 2016 Jul 8;11(7):e0158978. doi: 10.1371/journal.pone.0158978. eCollection 2016.

16.

Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.

Maurer MA, Tuller F, Gredler V, Berger T, Lutterotti A, Lünemann JD, Reindl M.

J Neuroimmunol. 2016 Jan 15;290:49-53. doi: 10.1016/j.jneuroim.2015.11.006. Epub 2015 Nov 19.

17.

Impact of glatiramer acetate on paraclinical markers of neuroprotection in multiple sclerosis: A prospective observational clinical trial.

Ehling R, Di Pauli F, Lackner P, Rainer C, Kraus V, Hegen H, Lutterotti A, Kuenz B, De Zordo T, Schocke M, Glatzl S, Löscher WN, Deisenhammer F, Reindl M, Berger T.

J Neuroimmunol. 2015 Oct 15;287:98-105. doi: 10.1016/j.jneuroim.2015.08.004. Epub 2015 Aug 10.

PMID:
26439969
18.

NMDA receptor antibodies: A rare association in inflammatory demyelinating diseases.

Ramberger M, Bsteh G, Schanda K, Höftberger R, Rostásy K, Baumann M, Aboulenein-Djamshidian F, Lutterotti A, Deisenhammer F, Berger T, Reindl M.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 13;2(5):e141. doi: 10.1212/NXI.0000000000000141. eCollection 2015 Oct.

19.

Non-convulsive status epilepticus with negative phenomena--a SMART syndrome variant.

Hametner E, Unterberger I, Lutterotti A, Beer R, Prieschl M, Grams AE, Donnemiller E, Stockhammer G.

Seizure. 2015 Feb;25:49-51. doi: 10.1016/j.seizure.2014.12.007. Epub 2014 Dec 23. No abstract available.

20.

Damping of monocular pendular nystagmus with vibration in a patient with multiple sclerosis.

Ehling R, Lutterotti A, Brenneis C, Zee DS, Beh SC, Kheradmand A.

Neurology. 2014 Nov 11;83(20):1879. doi: 10.1212/WNL.0000000000000995. No abstract available.

Supplemental Content

Loading ...
Support Center